Decreased Acute Otitis Media With Treatment Failure After Introduction of the Ten-valent Pneumococcal Haemophilus influenzae Protein D Conjugate Vaccine
- PMID: 29278616
- DOI: 10.1097/INF.0000000000001870
Decreased Acute Otitis Media With Treatment Failure After Introduction of the Ten-valent Pneumococcal Haemophilus influenzae Protein D Conjugate Vaccine
Abstract
Background: Acute otitis media (AOM) nonresponsive to antibiotics is most commonly caused by antibiotic-resistant Streptococcus pneumoniae and Haemophilus influenzae. A strategy for treating these infections with parenteral ceftriaxone was adopted at the Children's Hospital Iceland. The 10-valent pneumococcal H. influenzae protein D-conjugate vaccine was introduced into the vaccination program in Iceland in 2011. The aim was to study its effect on the incidence of AOM with treatment failure.
Methods: This retrospective observational study included children who visited the Children's Hospital Iceland because of AOM or received ceftriaxone, regardless of indication from 2008-2015. Incidence rate was calculated for prevaccine (2008-2011) and postvaccine (2012-2015) periods using person-years at risk within the hospital's referral region. Incidence rate ratio of ceftriaxone treatment episodes of AOM was calculated using the Mantel-Haenzel method adjusting for age. Incidence risk ratio of ceftriaxone treatment if presenting to the hospital with AOM was calculated to adjust for rate of AOM visits.
Results: Visits for AOM decreased from 47.5 to 33.9 visits per 1000 person-years, incidence rate ratio (IRR) 0.86 (95% confidence interval [CI]: 0.81-0.91), P < 0.001. Fewer AOM episodes were treated with ceftriaxone, decreasing from 6.49 to 2.96 treatment episodes per 1000 person-years, with an overall Mantel-Haenzel adjusted IRR 0.45 (95% CI: 0.37-0.54; P < 0.001). This remained significant after adjusting for the decrease in AOM visits, IRR 0.53 (95% CI: 0.44-0.63; P < 0.001).
Conclusions: Visits for AOM and ceftriaxone use decreased significantly after H. influenzae protein D-conjugate vaccine introduction. The observed decrease in ceftriaxone use is presumed to represent a decline in AOM with treatment failure, secondary to a decrease in resistant infections.
Similar articles
-
Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.Hum Vaccin Immunother. 2017 Jun 3;13(6):1-16. doi: 10.1080/21645515.2017.1287640. Epub 2017 Feb 25. Hum Vaccin Immunother. 2017. PMID: 28368738 Free PMC article. Clinical Trial.
-
Reduction in All-Cause Acute Otitis Media in Children <3 Years of Age in Primary Care Following Vaccination With 10-Valent Pneumococcal Haemophilus influenzae Protein-D Conjugate Vaccine: A Whole-Population Study.Clin Infect Dis. 2018 Sep 28;67(8):1213-1219. doi: 10.1093/cid/ciy233. Clin Infect Dis. 2018. PMID: 29617959
-
Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.PLoS Med. 2014 Jun 3;11(6):e1001657. doi: 10.1371/journal.pmed.1001657. eCollection 2014 Jun. PLoS Med. 2014. PMID: 24892763 Free PMC article. Clinical Trial.
-
Prevention of otitis media: now a reality?Vaccine. 2009 Sep 25;27(42):5748-54. doi: 10.1016/j.vaccine.2009.07.070. Epub 2009 Aug 8. Vaccine. 2009. PMID: 19666154 Review.
-
Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage.Expert Rev Vaccines. 2017 Jul;16(7):1-14. doi: 10.1080/14760584.2017.1333905. Epub 2017 Jun 7. Expert Rev Vaccines. 2017. PMID: 28571504 Review.
Cited by
-
Impact of the 10-valent pneumococcal conjugate vaccine on antimicrobial prescriptions in young children: a whole population study.BMC Infect Dis. 2018 Oct 4;18(1):505. doi: 10.1186/s12879-018-3416-y. BMC Infect Dis. 2018. PMID: 30286726 Free PMC article.
-
Increase in tympanostomy tube placements despite pneumococcal vaccination, a population-based study.Acta Paediatr. 2019 Aug;108(8):1527-1534. doi: 10.1111/apa.14724. Epub 2019 Feb 17. Acta Paediatr. 2019. PMID: 30667099 Free PMC article.
-
The impact and cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the paediatric immunisation programme in Iceland-A population-based time series analysis.PLoS One. 2021 Apr 8;16(4):e0249497. doi: 10.1371/journal.pone.0249497. eCollection 2021. PLoS One. 2021. PMID: 33831049 Free PMC article.
-
Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.Hum Vaccin Immunother. 2022 Dec 31;18(1):1942712. doi: 10.1080/21645515.2021.1942712. Epub 2021 Jul 28. Hum Vaccin Immunother. 2022. PMID: 34319865 Free PMC article.
-
Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media.Hum Vaccin Immunother. 2022 Dec 31;18(1):2013693. doi: 10.1080/21645515.2021.2013693. Epub 2022 Jan 12. Hum Vaccin Immunother. 2022. PMID: 35020530 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical